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Abstract
Introduction: The ano-inguinal lymphatic drainage (AILD) is located in the subcutaneous adipose tissue of the
proximal medial thigh. Currently, there are no recommendations for an inclusion of the ‘true’ AILD in the clinical target
volume (CTV) of definitive chemoradiation for anal cancer patients. To estimate the relevance of inguinal recurrence,
we compared the incidental dose to the AILD in anal cancer (AC) patients who were treated either with Volumetric Arc
Therapy – Intensity Modulated Radiation Therapy (VMAT-IMRT) or conventional 3D-radiation technique.
Methods: One VMAT-IMRT-plans and one 3D-plans were calculated on the same target volumes and identical dose
prescription in ten patients. We defined the volume of the AILD on the planning CT-scans based on the information of
new fluorescence methods. Furthermore, we defined several anatomical subvolumes of interest inside the AILD. We
examined and compared absolute and relative dosimetric parameters of the AILD and different anatomical subunits.
Results: The Dmean of the AILD was 40 Gy in the 3D-group and 38 Gy in the IMRT-group. Dmean and Dmedian as
well as the V30Gy of the AILD and all subvolumes of the caudal AILD were significant higher using 3D-RT compared to
IMRT. Even though the absolute differences were small, in the caudal aspect of the ano-inguinal lymphatic drainage
the V30Gy could be more than 10% less with VMAT-IMRT.
Conclusions: 3D-RT was slightly superior to IMRT in terms of dose coverage of the AILD. However, the absolute
differences were very small. Some relevant caudal parts of the AILD received an insufficient dose for treating potential
micrometastases. Particularly in high-risk situations, this may lead to inguinal recurrence and therefore the true deep
AILD should be included into the target volume in high risk patients.
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Purpose
A combined chemoradiation (CRT) protocol using IMRT is
the standard treatment regimen for anal cancer [1, 2]. The
anatomical definition of the lymphatic drainage of the anus
to the inguinal region is complex, and the literature on this
is inconsistent. In particular, the ano-inguinal lymphatic
drainage (AILD) pathway has long been undetectable with
traditional lymphangiography due to very small lymphatic
canals [3]. Therefore, the AILD has not been properly taken
into consideration for a long time, and inclusion of the elect-
ive CTV of the AILD is not recommended by standard con-
touring guidelines. Furthermore, CTV-recommendations
are generally based not on the “anatomical” drainage but on
the incidence of nodal metastases in a particular site [4, 5].
In the last years, new fluorescence-imaging methods have
been developed. Those help to define the area of the AILD
in real-time and transcutaneously [6, 7]. We recently pub-
lished an analysis in which, for the first time, surgeons and
radiation oncology specialists, presented a clearly defined
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anatomically area for the “true” AILD based on
fluorescence-imaging method. We evaluated the dose distri-
bution of VMAT-IMRT-treated anal cancer patients to this
defined volume, showing that, in particular, the caudal areas
of inguinal lymphatic drainage did not receive an adequate
prophylactic dose for micrometastatic spread [8].
The clinical relevance of inguinal lymph nodes in anal
carcinoma is not to be overlooked. Especially among pa-
tients with higher T-staging (T3 - T4) and those with
uninvolved inguinal nodes at the time of diagnosis, who
did not receive elective radiation to the groin, the in-
guinal recurrence rates can exceed 30 % [9–13]. If elect-
ive 3D-radiation therapy to the groin was performed
without inclusion of the AILD, inguinal lymph node re-
lapse would be considered quite rare. In an analysis of
167 patients treated between 1996 and 2004, Das et al.
reported only one inguinal relapse (0.6%) in a patient
with history of ipsilateral inguinal nodal involvement
[14]. The risk of inguinal lymph node recurrence in
IMRT treated patients is difficult to assess, as there are
just a few studies demonstrating patterns of recurrence.
However, even if the inguinal relapse rate in the study
with most patients (106) was low (about 4%), the results
indicate that using IMRT could lead to increased num-
bers of recurrence, especially if inguinal lymph node me-
tastases were present at diagnosis (3 of 4 cases with
relapse) [15]. Compared to 3D-techniques and field ar-
rangements, due to steep dose gradients, IMRT offers
the opportunity of dose-sparing to organs at risk (OAR)
at similar loco-regional control rates [16, 17]. Even
though IMRT is the recommended standard by now,
using this new technique we have already experienced
marginal misses in head and neck and also ano/rectal
cancer patients due to misunderstandings of anatomical
conditions (e. a. perirectal, presacral) [18–20].
Inguinal recurrence in IMRT-treated patients occurs
mostly in patients who already had positive inguinal nodes
at diagnosis. This fact raises the question, whether recur-
rence is due to insufficient dose to inguinal macroscopic
involved nodes or an insufficient dose to potential micro-
metastases in AILD. To prove the impact of radiation
techniques, we compared IMRT- versus 3D-techniques in
anal cancer patients regarding dose distribution to the
AILD. Our aim was to estimate whether the change to
IMRT as the new standard technique for anal carcinoma
patients could have led to insufficient dose for the treat-
ment of micrometastases in the area of the AILD.
Methods
Patient selection and radiation technique details
We selected ten patients with a diagnosis of anal cancer
and clinical not involved inguinal nodes who were
already treated with primary chemoradiation protocol
between 2012 and 2017. We prospectively generated a
standardized elective clinical target volume for anal can-
cer as recommended by RTOG [5] on the original plan-
ning CT scan with 3 mm slice thickness for each patient.
All patients were in prone position. Subsequently, we
calculated two plans for each individual, one for volu-
metric arc therapy (VMAT) and one 3-dimensional
(3D)-plan. All plans were created for a Varian Clinac®
DHX linear accelerator (Varian Medical Systems, Palo
Alto, CA, USA). Dose prescription for both radiation
techniques was 36 Gy (1.8 Gy single dose) to PTV1,
which included the primary tumor region (PTR), the
elective pelvic lymph nodes and the inguinal nodes and
subsequently 14.4 Gy (1.8 Gy single dose) to PTV2,
which includes the PTR and the elective pelvic nodes
without inguinal lymph nodes. Aim was, to cover the
primary tumor site and the pelvic lymph nodes with a
total dose of 50.4 Gy and the inguinal lymph nodes with
a total dose of 36 Gy (single dose 1.8 Gy). Dose con-
straints for organs at risk (OAR) (rectum, sigmoid, small
bowel, femoral head left & right, penis/scrotum or va-
gina/vulva, skin of AILD, urinary bladder) orientated on
Quantitative Analyses of Normal Tissue Effects in the
Clinic (QUANTEC) [21].
For VMAT, regularly 3 arcs in the main plan (PTV1)
and 2 arcs for the boost plan (PTV2) (6 or 15 MV) were
used. The dose was prescribed to the median of the
PTV (ICRU83).
For 3D-radiation-plans, we utilized 6–12 fields with
wedges (15–45°). Main fields were planned from poster-
ior and lateral. Segment fields were used to improve
dose coverage and dose homogeneity. The 3D planning
was done according to the technique used in the past.
Analogous to VMAT, the dose was prescribed to the me-
dian of the PTV (ICRU83). For both techniques we used
Eclipse 13.0 Treatment Planning System (Varian Medical
Systems, Palo Alto, CA, USA) for contouring and dose
comparison.
Definition of the AILD
We defined the AILD on each patient almost identical
to our previous AILD-fluorescence-study (Fig. 1a) [8].
The cranial border of the AILD (the upper ischioanal
fossa) was the origin of the levator ani muscle. The cau-
dal demarcation was defined 3 cm below the lower end
of the anal canal. On inguinal site, the ventral and med-
ial demarcation was the skin of the medial thigh; dorsal
was the connection line of the dorsal edge of the gluteal
muscles. The lateral demarcations were the adductor
muscles (anal) or the medial edge of the sartorius or
iliopsoas adductor muscles (inguinal).
In our previous study we demonstrated, that especially
the caudal parts of the AILD were insufficiently covered
by the 30 Gy isodose in IMRT-treated patients [8]. In
contrast, the cranial parts of the AILD (ischioanal fossa)
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were adjacent to the anal canal and usually covered by
higher doses. The interesting part of the AILD begins
where the first subcutaneous connective tissue connection
from the area of the anus to the inguinal lymph nodes
below the pubic bone exists. This connection is not in-
cluded into the CTV in various established contouring
guidelines [5, 22, 23]. Therefore, we also compared the
dose of different subvolumes of the AILD: We divided the
AILD into a cranial part (AILDcranial = ischiorectal fossa)
and a caudal part (AILDcaudal = first 3 cm below the anal
verge). Furthermore, we divided the AILDcaudal into
three different levels, each of 1 cm longitudinal extension
(Fig. 1b).
Dosimetric evaluation
We compared absolute (Dmean, Dmedian, D98%, D2%)
and relative dose parameters (V10-V50) of the AILD for
both radiation techniques. In addition, we analyzed dif-
ferent dose parameters to the AILDcranial, AILDcaudal
and Level1, Level2 and Level3, as represented in the
dose-volume histogram.
For all dose parameters of the OAR, a two-sided Wilcoxon
test was performed with SPSS 25.0 (SPSS Inc., Chicago, IL,
USA) to identify significant differences between the plans for




Nine of the ten patients had anal canal cancer, whereas
one patient had a T2 tumor of the anal margin. There
were two patients with T1, four patients with T2 and
two patients with T3 disease. Lymph node involvement
could be found in four patients. All positive nodes were
located in pelvic lymph nodes above the primary tumor.
In both groups the PTV was well covered by the pre-
scription dose of 36 Gy (PTV1) and 14.4 Gy (PTV2).
There was no statistically significant difference between
these parameters (p = 0.912). The measured volume of
the AILD was 943 cc. Dose constraints for organs at risk
(OAR) orientated on Quantitative Analyses of Normal
Tissue Effects in the Clinic (QUANTEC) were respected
for both radiation techniques.
Dosimetric analysis of the whole volume of the AILD
The dose parameters of the AILD hardly differed between
the two irradiation techniques (Table 1). Both, the Dmean
and the Dmedian of the AILD were significant lower using
IMRT compared to 3D-RT (p = 0.008; 9 = 0.017), even if
the absolute differences were just 1.8 Gy for Dmean and
3.3 Gy for Dmedian. Ninety-eight percent of this volume
was covered by 34Gy (IMRT) and 37Gy (3D) (p = 0,075).
There were no relevant differences in D98% however,
there was a small but significant difference in the D2%
(VMAT: 51.8 Gy, 3D-RT: 53.2).
Only in low dose range, the IMRTgroup had a non-signifi-
cant higher coverage of the AILD (96%) compared to
3D-radiation (87%). With higher doses (V20Gy-V50Gy),
more volume of the AILD was covered in the 3D-group,
though the differences never exceeded 6 %. The V10-V40Gy
were significantly higher with 3D conformal technique
(p = 0.008–0.021). Eighty-nine percent of the AILD was
covered with 20 Gy, 79 % with 30 Gy and 61 % with 40
Gy using 3D-RT, whereas 86 % of the AILD was
covered with 20 Gy, 73 % with 30 Gy and 54 % with 40
Gy using IMRT.
Dosimetric analysis of different subvolumes of the AILD
With a subdivision into different regions of interest, the
AILD can be examined more precisely (Table 2). The
cranial aspect of the AILD (AILDcranial), which largely
corresponds to the ischio-rectal fossa, encloses the anal
canal and thus the PTV. Unsurprisingly, here the Dmean
and Dmedian almost reached the prescription dose of
50.4 Gy regardless of the radiotherapy technique, and 98
% of the cranial volume was covered by 34 Gy (IMRT)
and 37 Gy (3D) (p = 0,075). Also the clinical relevant
V30Gy reached almost 100 % of the volume.
Fig. 1 The ano-inguinal lymphatic drainage (a) consist of a dorsal/cranial (ischiorectal fossa) and a ventral/caudal part (subcutaneous tissue from
the anus to inguinal site). The caudal part is currently not included into the elective CTV of the recommendations by RTOG. For dose comparison
we divided the caudal part in three different Levels (b), each with a longitudinal extension of 1 cm
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The interesting region is the caudal part of the AILD
(AILDcaudal), which cranially starts at the level of the
anal verge and falls below 3 cm of the anus and inguinal
nodes. Larger shares of this region are below or between
the target volumes proposed by the RTOG. This is also
reflected in the dose parameters. The Dmean and Dme-
dian were 32–35 Gy, independently of the radiation
techniques, with slight but significantly higher values
using 3D-radiotherapy. Ninety-eight percent of the vol-
ume was just covered by 11 Gy (both groups). Only a bit
more than half of volume in the IMRT-group and two
third of the volume in the 3D-group were covered by
30Gy (p = 0.011). The most cranial level (Level1) of
AILDcaudal was partly overlapping with the PTV of the
primary tumor and of the elective inguinal target volume
in all patients. Here, the Dmean and Dmedian in both
groups were at least 40 Gy and did not differ much from
each other, although the slightly higher values in the
3D-group were statistically significant. Also Level2, which
represents the volume which is 1-2 cm caudally of the anal
verge, was partly covered with the PTV, which is shown in
the D2% > 51Gy in both groups. The Dmean and Dme-
dian, which were both significantly higher with 3D-RT,
exceeded 33Gy with IMRT and 36Gy with 3D-RT. Com-
pared to Level1, the V30Gy was 18 % less using IMRT
(63%) and 12 % less using 3D-RT (73%). The huge dose
drop appeared starting 2 cm below the anal verge (Level3).
The minimal dose (D2%) fell below 50Gy. The Dmean
and Dmedian were smaller 30Gy for either technique.
Only one third of Level3 received 30Gy utilizing 3D-RT,
whereas the V30Gy was just 25 % with IMRT.
Discussion
In the current study we were able to show that the
Dmean and Dmedian as well as the V30Gy of the AILD
and all subvolumes of the caudal AILD were significantly
higher using 3D-RT compared to IMRT. Even though
the absolute differences were small in the caudal aspect
of the ano-inguinal lymphatic drainage, the V30Gy could
be more than 10 % less with VMAT-IMRT. With both
Table 1 Dose statistics of the ano-inguinal lymphatic drainage
(AILD) with two different radiation techniques
Technique
Dose (Gy)
Dmean Dmeadian D98% D2%
3D-RT 40,2 44,8 12,5 53,2
IMRT 38,0 41,5 11,6 51,8
p-value 0,008 0,017 0,441 0,007
Volume (%)
V10Gy V20Gy V30GY V40Gy V50Gy
3D-RT 87,1 88,5 78,8 61,0 31,3
IMRT 95,6 85,3 73,1 54,2 26,9
p-value 0,735 0,021 0,011 0,008 0,066
RT radiation therapy, Gy gray, 3D 3 dimensional, IMRT intensity modulated
radiation therapy
Boldface indicates values that are statistically significant
Table 2 Dose statistics of different subvolumes inside the ano-inguinal lymphatic drainage (AILD) with two different radiation
techniques
Structure Technique Dose (Gy) Volume (%)
Dmean Dmeadian D98% D2% V30Gy
AILDcranial 3D-RT 49,0 50,7 36,9 53,3 98,7
IMRT 47,3 49,5 33,6 51,9 98,5
p-value 0,008 0,008 0,075 0,008 0,236
AILDcaudal 3D-RT 34,7 35,4 11,3 52,3 66,5
IMRT 32,1 32,0 10,7 51,4 57,0
p-value 0,011 0,011 0,514 0,018 0,011
Level1 3D-RT 41,2 42,9 22,4 52,5 85,3
IMRT 39,5 40,4 21,6 51,6 81,0
p-value 0,013 0,015 0,285 0,011 0,110
Level2 3D-RT 36,5 37,4 15,4 51,9 73,4
IMRT 33,8 33,7 15,6 51,4 62,6
p-value 0,011 0,012 0,722 0,183 0,008
Level3 3D-RT 26,3 25,0 9,9 48,5 36,0
IMRT 22,3 20,1 9,5 44,4 25,2
p-value 0,011 0,015 0,813 0,173 0,011
RT radiation therapy, AILD ano-inguinal lymphatic drainage, Gy gray, 3D 3 dimensional, IMRT intensity modulated radiation therapy
Level1: 1 cm of AILD caudally of the anal verge, Level2: 1-2 cm of AILD caudally of the anal verge, Level3: 3 cm of AILD caudally of the anal verge
Boldface indicates values that are statistically significant
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techniques a relevant volume of the AILD was not cov-
ered by 30Gy. The results for the whole volume of the
AILD were similar to our study in which we retrospect-
ively analyzed the dose to the AILD in IMRT-treated pa-
tients [8]. Although the dose prescription in this study
was slightly different, the Dmean was 41Gy and V30Gy
was 76 % compared to 38 Gy and senventy-3 % in the
present study.
Interpretation of dose distribution in context with
anatomical conditions of the AILD
We chose the V30Gy as an important dose parameter
because RTOG98–11 used 30.6 Gy for elective irradi-
ation of the groin in patients with uninvolved inguinal
nodes and therefore should be considered as sufficient
for treatment of micrometastases. The V30Gy of the
AILD was significant higher for 3D-RT (79%) than for
IMRT-treated patients (73%). However, in some critical
areas of the caudal AILD (Level2), the differences
reached more than 10 % (73.4% versus 62.6%).
The direct drainage from the anus to inguinal site is
on ventral site of the perineal pouch. Below the pubic
symphysis, branches of the pudendal vessels and the first
fat tissue components of the ischioanal fossa reach the
external genitalia following the adductor muscles (lat-
eral) and the skin (medial) [24]. We chose this area as
the first level of our anatomically detailed breakdown of
dose distribution (Level1). The anus and inguinal site at
this level were covered by the previous PTV and re-
ceived adequate dose with both radiation techniques.
For this critical level, the V30Gy was 85 % with 3D-RT
and only 4 % lower (81%) with IMRT. The absolute dif-
ferences are indeed small and it would be daring to as-
sume that these small differences increase the risk of
inguinal recurrences.
Around 1 cm below this level we defined Level2. The
differences in dose distribution between the two tech-
niques increased. Figure 2 shows the 30Gy isodose (color
wash) in a selected patient using 3D-RT (2a) or IMRT
(2b). The caudal parts of the AILD were properly covered
with 3D-RT, whereas in IMRT the V30Gy was more con-
formal surrounding the PTV, and less volume of the AILD
was covered. Ultimately, this region could be the cause of
regional recurrences in some patients with high risk tu-
mors treated with IMRT. With immune-fluorescence
methods we were previously able to show the AILD to fall
about 3 cm below the level of the anal verge. This level
(Level3) is the most caudal potential lymphatic drainage
of the anal verge and unlikely to contain micrometastases
in low risk tumors of the anal canal. Since inguinal recur-
rences rarely occur 3 cm below the primary tumor, we do
not expect this level to be responsible for inguinal relapse
in the vast majority of cases. Nevertheless, in high risk
anal cancer, especially for big tumors (≥ T3) of the anal
verge with a high number of positive inguinal and pelvic
lymph nodes at diagnose, this part of the AILD could be
of clinical relevance. The change from 3D-RT to IMRT
might have an impact regarding inguinal recurrence in
those patients.
Clinical relevance of elective radiation of lymphatic-drainage
The most common grade 3 or 4 toxicity in the two big
prospective trials (2D- or 3D-techniques) was radio
dermatitis. In both trials (RTOG98–11 and ART II)
grade ≥ 3 skin toxicity was 48 % in the mitomycin-based
arm [1, 2]. Scher et al. summarized 8 IMRT-studies which
demonstrated skin toxicity after radiation of anal cancer
patients (n = 39–78) [25]. Dose to the inguinal lymph
nodes was mainly 45Gy. Grade ≥ 3 skin toxicity ranged
from zero to 42 % (mean: 23%). With IMRT-techniques
≥3, skin toxicity was significantly reduced in RTOG-0529
(23%), whereas in other IMRT-studies it could reach 69 %
[15, 26, 27]. Because of the fact that the critical part of the
ano-inguinal lymphatic drainage is located subcutaneously
on the medial thigh, we would expect an increase in this
relevant toxicity. Furthermore, the genito-urinary side ef-
fects might increase [28].
In order to ascertain the clinical benefit of inclusion of
the AILD into the CTV, the number and pattern of
Fig. 2 Axial CT slide 1.5 cm below the lower end of the anal canal in one patient. 30 Gy is represented in colorwash (red area). In this case, about
75% of ano-inguinal lymphatic drainage (cyan) is covered with 3D-RT (a) and just about 50% is covered using IMRT (b)
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recurrence are important. Overall, the data on IMRT-
treated patients and explicit inguinal recurrences and
patterns of spread are less well explored. In the RTOG-
0529-study, loco regional failure was 13 % after 4 years.
The Study did not show any detailed differentiation of the
site of failure, though [17]. Only Tomasoa et al. provided
detailed data regarding the number and patterns of inguinal
recurrence. In a retrospective analysis of 106 patients
treated by SIB-IMRT, four patients had inguinal relapse
(4%) [15]. Three out of these four patients had initially in-
volved inguinal nodes. A total dose to lymph nodes of 49.5
à 1.5 Gy was given, which means a higher biological dose
than in conventional techniques. The authors (Tomasoa et
al.) compared this to similar results of Wright et al. (3-field
technique) and mentioned that more conformal techniques
(IMRT) with higher total dose might not reduce inguinal
relapse [15, 29]. This indicates that microscopic disease in
the AILD but not the lymph nodes themselves might be re-
sponsible for inguinal relapse. Another important finding of
these studies was that none of inguinal recurrences oc-
curred below approximately 1 cm of the level of the anal
canal. Wright et al. however, could show that inguinal re-
currences arise up to 3 cm below the anal verge (conven-
tional technique) [29]. Up to this date, insufficient data
concerning inguinal recurrence in anal carcinoma is avail-
able. However, there are a few cases of inguinal relapse even
in inguinal-treated patients. To balance the relevant skin
toxicity with the risk of inguinal relapse in high risk tumors
(T3-T4, inguinal involvement at diagnosis, anal verge), an
inclusion of the AILD into the target volume could be
useful.
Conclusion
3D-RT was slightly superior to IMRT in terms of dose
coverage of the AILD. However, the absolute differences
were very small. Some relevant caudal parts of the AILD
received an insufficient dose for treating potential micro-
metastases. Particularly in high-risk situations, this may
lead to inguinal recurrence and therefore the true deep
AILD should be included into the target volume in high
risk patients.
Abbreviations
2D/3D: 2/3 dimensional; AILD: Ano-inguinale lymphatic drainage;
CRT: Chemoradiation therapy; CTV: Clinical target volume; E. a.: For example;
Gy: Gray; IMRT: Intensity modulated radiotherapy; LD: Lymphatic drainage;
OAR: Organs at risk; PET: Positron emission tomography; PTR: Primary tumor
region; PTV: Planning target volume; RT: Radiation therapy; SIB: Simultaneously




This research did not receive any specific grant from funding agencies, the
public, commercial, or not-for-profit sectors.
Availability of data and materials
The present data is summarized in this paper (METHODS). The complete
dataset can be retrieved from the authors upon formal request from
interested readers.
Authors’ contributions
DH and SEC treated the patients and provided the data and study infrastructure. DH
and HD developed the study design, collected, and interpreted data, performed
statistical analysis and drafted the manuscript. DH made substantial contributions to
conception and design of the study, interpreted data and revised the manuscript.
MO calculated the different radiation plans (IMRT and 3D-RT). CH, CS, SM, KB, JCP
and SEC contributed significantly to the discussion and interpretation of the results.
CH made the basic research regarding fluorescence detection of the AILD. HD and
DH made the main contributions to conception and design of the study, analysed
and interpreted data and drafted the manuscript. All co-authors read and revised the
manuscript. The final version of the manuscript was approved by all co-authors.
Ethics approval and consent to participate
The study was performed in accordance with the ethics standards at the
Techniqueal University of Munich (TUM) (ethical vote: 28.02.2018s, 88/18 S).




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Radiation Oncology, Klinikum rechts der Isar, TU München,
Ismaninger Str. 22, 81675 Munich, Germany. 2Department for Hand-, Plastic
and Reconstructive Surgery, Burn Centre, BG-Trauma Centre Ludwigshafen/
Rhine, University of Heidelberg, Ludwig-Guttmann-Str. 13, 67071
Ludwigshafen, Germany. 3Institute for innovative Radiotherapie (iRT),
Helmholtz Zentrum München, Ingolstädter Landstr. 1, Neuherberg, Germany.
4Deutsches Konsortium für translationale Krebsforschung (DKTK), Partner SiTe
Munich, Munich, Germany.
Received: 18 July 2018 Accepted: 6 November 2018
References
1. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR Jr, et
al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and
radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
JAMA. 2008;299(16):1914–21. https://doi.org/10.1001/jama.299.16.1914.
2. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS,
Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without
maintenance chemotherapy for treatment of squamous-cell carcinoma of
the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial.
Lancet Oncol. 2013;14(6):516–24. https://doi.org/10.1016/S1470-
2045(13)70086-X.
3. Fuchs WA. Lymphographie und Tumordiagnostik. Berlin; Heidelberg; New
York: Springer Verlag; 1965. p. 66.
4. Lee NY, Lu JJ. Target volume delineation and field setup: a practical guide
for conformal and intensity modulated radiation therapy. Berlin, Heidelberg:
Springer; 2013.
5. Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al.
Elective clinical target volumes for conformal therapy in anorectal cancer: a
radiation therapy oncology group consensus panel contouring atlas. Int J
Radiat Oncol Biol Phys. 2009;74(3):824–30. https://doi.org/10.1016/j.ijrobp.
2008.08.070.
6. Hirche C, Dresel S, Krempien R, Hünerbein M. Sentinel node biopsy by
indocyanine green retention fluorescence detection for inguinal lymph
node staging of anal cancer: preliminary experience. Ann Surg Oncol. 2010;
17(9):2357–62. https://doi.org/10.1245/s10434-010-1010-7.
Dapper et al. Radiation Oncology          (2018) 13:227 Page 6 of 7
7. Doniga SG. Die Fluoreszenzfarbstoff-gestützte Sentinel-Lymphknoten-
Biopsie mittels Indocyanin Grün bei solitären Tumoren [@Berlin, Univ.-
Medizin, Diss. 2013]. Verfügbar unter: http://www.diss.fu-berlin.de/diss/
receive/FUDISS_thesis_000000094271.
8. Dapper H, Habl G, Hirche C, Münch S, Oechsner M, Mayinger M, et al.
Dosimetric quantification of the incidental irradiation of the ‘true’ (deep)
ano-inguinal lymphatic drainage of anal cancer patients not described in
conventional contouring guidelines. Acta Oncol. 2018:1–6. https://doi.org/
10.1080/0284186X.2017.1415459.
9. Ortholan C, Resbeut M, Hannoun-Levi J-M, Teissier E, Gerard J-P, Ronchin P,
et al. Anal canal cancer: management of inguinal nodes and benefit of
prophylactic inguinal irradiation (CORS-03 study). Int J Radiat Oncol Biol
Phys. 2012;82(5):1988–95. https://doi.org/10.1016/j.ijrobp.2011.02.010.
10. Blinde SE, Schasfoort R, Mens JW, Verhoef C, Olofsen M, Nuyttens JJ.
Inguinal lymph node recurrence in the untreated groin of patients with
anal carcinoma. Dis Colon Rectum. 2014;57(5):578–84. https://doi.org/10.
1097/DCR.0000000000000050.
11. Tomaszewski JM, Link E, Leong T, Heriot A, Vazquez M, Chander S, et al.
Twenty-five-year experience with radical chemoradiation for anal cancer. Int
J Radiat Oncol Biol Phys. 2012;83(2):552–8. https://doi.org/10.1016/j.ijrobp.
2011.07.007.
12. Nilsson PJ, Svensson C, Goldman S, Ljungqvist O, Glimelius B. Epidermoid
anal cancer: a review of a population-based series of 308 consecutive
patients treated according to prospective protocols. Int J Radiat Oncol Biol
Phys. 2005;61(1):92–102. https://doi.org/10.1016/j.ijrobp.2004.03.034.
13. James RD, Pointon RS, Martin S. Local radiotherapy in the management of
squamous carcinoma of the anus. Br J Surg. 1985;72(4):282–5.
14. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al.
Predictors and patterns of recurrence after definitive chemoradiation for
anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800. https://doi.org/
10.1016/j.ijrobp.2006.12.052.
15. Tomasoa NB, Meulendijks D, Nijkamp J, Cats A, Dewit L. Clinical outcome in
patients treated with simultaneous integrated boost - intensity modulated
radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for
squamous cell carcinoma of the anal canal. Acta Oncol. 2016;55(6):760–6.
https://doi.org/10.3109/0284186X.2015.1124141.
16. Bryant AK, Huynh-Le MP, Simpson DR, Murphy JD. Comparative
effectiveness of IMRT and 3D comparative effectiveness of IMRT and 3D
conformal radiation therapy for anal Cancer. Int J Radiat Oncol Biol Phys.
2017;99.
17. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al.
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated
radiation therapy in combination with 5-fluorouracil and mitomycin-C for the
reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol
Biol Phys. 2013;86(1):27–33. https://doi.org/10.1016/j.ijrobp.2012.09.023.
18. Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of
anal cancer. J Natl Compr Cancer Netw. 2010;8(1):123–9.
19. Chen AM, Farwell DG, Luu Q, Chen LM, Vijayakumar S, Purdy JA. Marginal
misses after postoperative intensity-modulated radiotherapy for head and
neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1423–9. https://doi.org/
10.1016/j.ijrobp.2010.04.011.
20. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after
definitive intensity-modulated radiotherapy for head and neck cancer. Int J
Radiat Oncol Biol Phys. 2008;70(3):660–5. https://doi.org/10.1016/j.ijrobp.
2007.09.018.
21. Marks LB, Yorke ED, Jackson A, ten Haken RK, Constine LS, Eisbruch A, et al.
Use of normal tissue complication probability models in the clinic. Int J
Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9. https://doi.org/10.1016/j.
ijrobp.2009.07.1754.
22. Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian
gastrointestinal trials group (AGITG) contouring atlas and planning guidelines
for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol
Phys. 2012;83(5):1455–62. https://doi.org/10.1016/j.ijrobp.2011.12.058.
23. R Muirhead, RA Adams, DC Gilbert, M Harrison, R Glynne-Jones, D Sebag-
Montefiore, MA Hawkins. National guidance for IMRT in anal national guidance
for IMRT in anal cancer: the CRUK/MRC Oxford Institute for Radiation
Oncology, Oxford, UK; School of Medicine, Cardiff University, Cardiff, UK; Sussex
Cancer Centre, Royal Sussex County Hospital, Brighton, UK; Mount Vernon
Hospital, Northwood, UK; University of Leeds, St James Institute of Oncology,
Leeds, UK; 2016 [Stand: 08.08.2018]. Verfügbar unter: http://analimrtguidance.
co.uk/national-anal-imrt-guidance-v3.pdf.
24. Aumüller G, Wolff W. Duale Reihe - Anatomie. Duale Reihe 1. Aufl. Stuttgart:
Thieme; 2007. Duale Reihe
25. Scher ED, Ahmed I, Yue NJ, Jabbour SK. Technical aspects of radiation
therapy for anal cancer. J Gastrointest Oncol. 2014;5(3):198–211. https://doi.
org/10.3978/j.issn.2078-6891.2014.026.
26. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al.
Intensity-modulated radiation therapy with concurrent chemotherapy for
anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37(5):461–6.
https://doi.org/10.1097/COC.0b013e31827e52a3.
27. Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens
JHM, et al. Chemoradiotherapy with capecitabine for locally advanced anal
carcinoma: an alternative treatment option. Br J Cancer. 2014;111(9):1726–
33. https://doi.org/10.1038/bjc.2014.467.
28. Koeck J, Lohr F, Buergy D, Büsing K, Trunk MJ, Wenz F, Mai S. Genital invasion
or perigenital spread may pose a risk of marginal misses for Intensity
Modulated Radiotherapy (IMRT) in anal cancer: BioMed Central Ltd; 2016.
29. Wright JL, Patil SM, Temple LKF, Minsky BD, Saltz LB, Goodman KA.
Squamous cell carcinoma of the anal canal: patterns and predictors of
failure and implications for intensity-modulated radiation treatment
planning. Int J Radiat Oncol Biol Phys. 2010;78(4):1064–72. https://doi.org/10.
1016/j.ijrobp.2009.09.029.
Dapper et al. Radiation Oncology          (2018) 13:227 Page 7 of 7
